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Abstract Metformin is an effective agent with a good safety
profile that is widely used as a first-line treatment for type 2
diabetes, yet its mechanisms of action and variability in terms
of efficacy and side effects remain poorly understood.
Although the liver is recognised as a major site of metformin
pharmacodynamics, recent evidence also implicates the gut as
an important site of action. Metformin has a number of actions
within the gut. It increases intestinal glucose uptake and lac-
tate production, increases GLP-1 concentrations and the bile
acid pool within the intestine, and alters the microbiome. A
novel delayed-release preparation of metformin has recently
been shown to improve glycaemic control to a similar extent
to immediate-release metformin, but with less systemic expo-
sure. We believe that metformin response and tolerance is
intrinsically linked with the gut. This review examines the
passage of metformin through the gut, and how this can affect
the efficacy of metformin treatment in the individual, and
contribute to the side effects associated with metformin
intolerance.
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Abbreviations
AMPK 5′-AMP-activated protein kinase
CHT Choline transporter
DPP4 Dipeptidyl peptidase-4
DR Delayed release
18F-FDG 18F-fluorodeoxyglucose
FXR Farnesoid X receptor
GI Gastrointestinal
GIMM Gastrointestinal microbiome modulator
GIP Gastric inhibitory polypeptide
GLP-1 Glucagon-like peptide 1
GoDARTS Genetics of Diabetes and Audit Research
Tayside Study
5-HT Serotonin
NMDA N-methyl-D-aspartate
OCT Organic cation transporter
PET-CT Positron emission tomography–computed
tomography
PKA Protein kinase A
PMAT Plasma membrane monoamine transporter
SERT Serotonin transporter
SGLT1 Sodium–glucose transporter 1
Introduction
Metformin—dimethylbiguanide—is an oral glucose-lowering
agent. Its origins can be traced to Galega officinalis, also
known as French lilac or goat’s rue [1]. In the early 20th
century it was noted to lower blood glucose concentrations
in animals, but it was not until the 1950s that Jean Sterne
studied dimethylbiguanide and subsequently developed
‘Glucophage’ [2].
Over the last 15 years, metformin has become the first-
line agent for the treatment of type 2 diabetes, as noted in
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several international guidelines, including the ADA-EASD
guidelines [3]. Metformin has had a chequered history—it
was initially eclipsed by phenformin, which was with-
drawn in the late 1970s after it was discovered to be
associated with lactic acidosis [4]. The lower propensity
of metformin for hyperlactataemia [5] and success in sev-
eral large randomised controlled clinical trials, such as the
UK Prospective Diabetes Study (UKPDS) [6], confirmed
its clinical benefit. It is widely recognised that metformin
improves glycaemic control with a good safety profile,
weight neutrality or weight loss, lack of associated
hypoglycaemia, reduced cardiovascular mortality and low
cost [3]. However, a large proportion of patients cannot
tolerate the medication in adequate amounts because of its
associated side effects. Up to 25% of patients suffer
metformin-associated gastrointestinal (GI) side-effects, with
approximately 5% unable to tolerate metformin at all [7].
In addition to this interindividual variation in side effects,
there is variability in the efficacy of metformin. There are
likely to be a number of factors to account for this variability
in efficacy, for example, our group (Zhou et al) recently
established that the glycaemic response to metformin is
moderately heritable, i.e. due in part to genetic variation [8].
In this review we will focus on the effects of metformin on
the gut and how its action within the intestine and on the intes-
tinal enterocytes can explain at least some of the glucose-
lowering effects of metformin, the increase in lactate concen-
trations and GI side-effects of this commonly used drug.
Summary of key points
• Metformin uptake is saturable and dose-dependent, con-
sistent with a predominantly transporter-dependent
mechanism. Uptake and tolerance could be affected by
genetic variation in the transporters, or by transporter-
inhibiting drugs
• Metformin increases glucose uptake in the intestine, and
subsequently increases lactate concentrations within the
enterocyte. This may contribute to metformin intolerance
• Metformin increases plasma GLP-1 concentrations,
though the mechanism is unclear. This could be direct or
indirect. The effect of metformin on DPP-4 is likely to be
small
• Metformin may, in part, utilise a gut–brain–liver axis to
exert its pharmacodynamic effect
• Metformin increases the bile acid pool within the intes-
tine, which may affect stool consistency, GLP-1 secre-
tion, cholesterol levels and the microbiome
• Metformin alters the microbiome, which may improve
glucose tolerance, but, conversely, may play a role in
metformin intolerance
Intestinal transport of metformin
Metformin is usually taken orally as the hydrochloride salt, in a
tablet formulation. It exists largely as a hydrophilic cationic
species at physiological pH, and has low lipid solubility, mak-
ing rapid passive diffusion of metformin through cell mem-
branes unlikely [4, 9]. Absorption of immediate-release formu-
lations of metformin is largely confined to the small intestine,
with negligible absorption in the stomach or large intestine [4,
10, 11]. In humans, intravenous administration of metformin
results in rapid renal elimination, with little or no metformin
detectable in the faeces [10], consistent with negligible biliary
or GI secretion of metformin. However, in a mouse model of
diabetes, intravenous administration of metformin does lead to
accumulation of metformin in the enterocytes—most notably
in the small intestine [12]. Oral bioavailability of metformin is
between 50% and 60%, with approximately 30% dose recov-
ery of unchanged metformin from faeces. Bioavailability is
affected by gastric motility and may be reduced by high-fat
meals [4]. The metformin concentration in the jejunum peaks
at 500 μg/g, 30–300 times greater than plasma concentrations
[13], highlighting the small intestine as an important site of
metformin uptake.
Modified-release formulations of metformin have been de-
veloped to spread the absorption of metformin along the gut
and thereby reduce local concentrations of the drug, with the
aim of increasing its tolerability. Metformin MR (modified-
release) uses a dual polymer matrix to delay the transit and
slow the release of metformin in the gut. On contact with fluid
from the GI tract, the tablet swells, and the metformin is re-
leased as the polymer gradually breaks down [14]. A new met-
formin formulation has recently been developed, metformin
DR (delayed-release), which is formulated to target the ileum
via pH-dependent dissolution of the tablet. Compared with
metformin IR (immediate-release) or metformin XR (extend-
ed-release), the bioavailability ofmetformin DR is lower, yet its
glucose-lowering efficacy is similar, despite lower systemic
metformin exposure [15]. This again highlights the ileum as a
site of uptake and as an important site of action of metformin in
lowering blood glucose.
Metformin uptake is saturable and dose-dependent [10,
16], consistent with the theory that it is mostly transporter-
dependent. Studies in Caco-2 cell monolayers (a cellular mod-
el of human intestinal epithelium) have shown that metformin
is efficiently taken up across the apical (luminal-facing) sur-
face of enterocytes via bidirectional transporters, but that ef-
flux across the basolateral surface of enterocytes is limited,
resulting in the accumulation of metformin in the epithelium
[16], possibly accounting for the greatly increased metformin
concentration seen in these cells. To account for the presence
of metformin in the portal circulation, some paracellular
uptake was postulated, with metformin diffusing passively.
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Several transporters, for which metformin is a likely sub-
strate, have been identified e.g. organic cation transporter
(OCT) 1–3, plasma membrane monoamine transporter
(PMAT), multidrug and toxin extrusion protein (MATE) 1–
2, serotonin transporter (SERT) and high-affinity choline
transporter (CHT). OCTs are members of solute carrier family
22 (SLC22), initially described in 1994, and encoded on chro-
mosome 6q26 [17]. OCTs are expressed in several tissues,
including the intestine, liver, kidney, brain, muscle and heart.
OCT1 is predominantly expressed in the liver, but plays an
important role in the transfer of cations, including metformin,
from the gut lumen to the interstitium [18]. Although initial
reports localised OCT1 to the basolateral membrane [19],
more recent reports place OCT1 on the apical surface of in-
testinal epithelial cells [20, 21]. OCT2 is expressed mainly in
the kidney and is partly responsible for the renal excretion of
metformin [18]. OCT3 is mainly expressed in the skeletal
muscle, but is also expressed in the intestine. Interestingly,
OCT3 is associated with metformin uptake and efflux in the
salivary glands, which may account for the dysgeusia associ-
ated with metformin treatment [22]. PMAT was originally
identified as a monoamine transporter from the equilibrative
nucleoside transporter (ENT) family, found predominantly in
the brain and central nervous system [23, 24]. It was later
recognised that PMAT was polyspecific and found in many
tissues throughout the body, including the intestine, where it
transports metformin with comparable affinity to the OCTs
[25]. PMAT is localised to the tips of the mucosal epithelial
layer, suggesting that PMAT has an integral role in metformin
uptake [25].
To investigate which transporters are involved in the trans-
port of metformin across the apical surface of enterocytes,
Han et al used pharmacological inhibitors and knockdown
studies in single transporter-expressing CHO (Chinese ham-
ster ovary) cells and Caco-2 cell monolayers [20]. They con-
cluded that the main transporters of metformin are OCT1,
PMAT, SERT and CHT, accounting for approximately 25%,
20%, 20% and 15% of apical metformin transport, respective-
ly. However, comparison of the expression of these trans-
porters in Caco-2 cells vs human jejunum using western blot
analysis revealed that the expression of all four proteins was
significantly higher in Caco-2 cells, with the expression of
CHT in human jejunum barely detectable [20]. Therefore,
direct evidence of the in vivo contribution of CHT to metfor-
min uptake is still lacking, leaving only OCT1, PMAT and
SERT as likely metformin transporters in the human intestine.
There are well-documented, relatively common loss-of-
function variants in human OCT1, and genetic variation in
OCT1 has been investigated by a number of groups in relation
to pharmacokinetics, efficacy and GI intolerance [7, 26–29].
The impact of variants in PMAT [30] and SERT on these
outcomes needs to be assessed.
IntestinalOCT1 transport andmetformin pharmacokinetics
and efficacyAsOCT1 is probably apically expressed it is most
likely to influence local concentrations of metformin in the gut
(lumen and enterocytes), rather than transfer into the blood.
Consistent with this interpretation, a recent study concluded
that OCT1 variants with loss of function do not alter metformin
concentrations in healthy volunteers titrated to 1 g/day of met-
formin [27]. An initial report that OCT1 variants altered the
glycaemic response to metformin in a clinical trial [28] was
not confirmed in a recent re-analysis that took account of the
baseline HbA1c level [29]. This is consistent with a report by
our group (Zhou et al) on the Genetics of Diabetes Audit and
Research Tayside Study (GoDARTS) data, where we found no
effect on the glycaemic response to metformin in a large pop-
ulation of patients with type 2 diabetes [31].
Intestinal OCT1 transport and GI intolerance with
metformin Given the role of OCT1 in potentially altering
local concentrations of metformin, our group (Dujic et al) pro-
posed that a reduction in function of OCT1might alter the risk
of GI intolerance in patients treated with metformin [7]. In this
study, GoDARTS data were analysed to assess the effect of
OCT1 (also known as SLC22A1) genotype and the use of
OCT1-inhibiting drugs on the incidence of metformin intoler-
ance in a large population of patients with type 2 diabetes.
Those with two reduced function OCT1 alleles had a more
than twofold increase in the odds for metformin intolerance
(p<0.001). This increased to an over fourfold increase in the
odds for intolerance in patients with two reduced function
OCT1 alleles who were also treated with OCT1-inhibiting
drugs (p<0.001) [7]. If confirmed by a clinical trial, this could
inform the clinical application of metformin such that, for
example, drugs known to interact with OCT1 could be re-
placed with alternatives, allowing improved tolerance to met-
formin and enabling optimal metformin dosing.
Metformin, glucose uptake and anaerobic
metabolism
Metformin increases gut glucose uptake and utilisation It
has been known for some time that metformin increases glu-
cose uptake and utilisation in the human intestine, resulting in
an increase in lactate production in enterocytes [12, 13].
Interestingly, the effect of metformin on gut glucose utilisation
is well known to radiologists, as metformin use will interfere
with imaging by positron emission tomography–computed
tomography (PET-CT). This functional imaging technique
uses positron-emitting 18F-fluorodeoxyglucose (18F-FDG) as
a non-metabolised glucose analogue. The uptake of 18F-FDG
is a marker of glucose uptake and, therefore, glucose
utilisation, which is a measure of the metabolic activity of
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tissue. PET-CT is commonly used for the diagnosis, staging
and monitoring of the response to treatment, of certain cancers
[32]. However, patients taking metformin have diffusely in-
creased 18F-FDG uptake in the colon and small intestine on
PET-CT [33–35], as can be seen in Fig. 1. This confirms that
metformin causes increased glucose uptake in the gut. It also
poses a significant risk of false-negative imaging results when
assessing for colonic or genitourinary tumours. For this reason
it is recommended that metformin be discontinued for at least
48 h prior to a PET-CT procedure/scan [33, 35].
The mechanism whereby metformin increases gut glucose
uptake and utilisation remains unclear [36–40]. In one study,
metformin reduced the activity of sodium–glucose transporter
1 (SGLT1), but increased the recruitment of GLUT2 to the
apical membrane of rat jejunum [38]; a study assessing the
response to 5′-AMP-activated protein kinase (AMPK) activa-
tors (5-aminoimidazole-4-carboxamide ribonucleotide
[AICAR] and metformin) suggests GLUT2 localisation to
the apical membrane is mediated via rapid AMPK phosphor-
ylation [38, 39]. Themechanism of glucose absorption and the
role of GLUT2 in this process remains the subject of debate
[40]. However, in fasting lean rodents GLUT2 is located on
the basolateral membrane and is only recruited to the apical
membrane of the enterocyte following postprandial glucose
stimulation of SGLT1 [41], whereas insulin results in the
internalisation of GLUT2. Interestingly, fasting obese
humans, unlike fasting lean individuals, have persistent
GLUT2 abundance in the apical membrane, signifying dys-
regulation of glucose sensing and transfer [41].
Metformin and lactate production As metformin treatment
increases the uptake and utilisation of glucose, there is a sub-
sequent increase in plasma lactate. Both the gut and liver are
implicated as the main sources of metformin-related lactate
production. In the gut, metformin increases the uptake and
anaerobic metabolism of glucose, contributing to the rise in
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Fig. 1 Some of the actions of metformin within the GI tract. The upward
arrows indicate increases. DPP4, dipeptidyl peptidase-4; FXR, farnesoid
X receptor; FDG, fluorodeoxyglucose; GLP-1, glucagon-like peptide-1;
OCT, organic cation transporter; PMAT, plasma membrane monoamine
transporter; SERT, serotonin transporter
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lactate associated with metformin treatment [12, 13, 42–49].
In rat hepatocytes, metformin inhibits mitochondrial glycero-
phosphate dehydrogenase, reducing the conversion of cyto-
solic lactate into pyruvate [42]. This build-up of intracellular
lactate results in its release into the plasma. Observational data
indicate that metformin causes a rise in fasting and average
lactate levels [43], with an average increase (adjusted for plas-
ma glucose and BMI) of 0.16 mmol/l compared with diet or
sulfonylurea treatment.
Several studies have attempted to localise the lactate pro-
duction associatedwithmetformin treatment [44–49]. Perhaps
most convincingly, rat studies in which plasma glucose and
lactate levels were measured in the inferior vena cava, hepatic
vein, hepatic portal vein and the aorta demonstrated that the
plasma lactate concentration peaks in the hepatic portal vein,
with a corresponding drop in the plasma glucose concentra-
tion. This implicates the intestine as the main site of
metformin-associated anaerobic glucose utilisation and lactate
production [44]. Ring biopsies taken from the jejunum and
ileum of these rats after intrajejunal metformin infusion con-
firmed a 10% increase in intestinal lactate concentration [44].
These findings were confirmed in humans by assessment of
lactate concentrations in jejunal biopsies incubated with and
without metformin [13]. Cells incubated in solution with met-
formin had a higher lactate concentration (an increase of up to
35%) than those incubated in solution lacking metformin.
These results provide corroborative evidence that metformin
increases gut utilisation of glucose and subsequent lactate pro-
duction. As a complementary explanation, lactate production
with metformin treatment may be due to its action on the gut
microbiome (see later), by inhibition of glycerophosphate de-
hydrogenase, which is found in some colonic bacteria. This
raises the question of local lactate concentrations contributing
to the GI symptoms associated with metformin intolerance. As
yet there is no clinical evidence to support this theory, but it
warrants further investigation.
Gut-related peptides
Metformin and glucagon-like peptide 1Metformin treatment
has been shown to increase the glucagon-like peptide 1 (GLP-1)
concentration in both mouse and human studies [50–63]. GLP-1
is secreted from L cells, which are distributed throughout the
intestine, but are highly concentrated in the ileum. GLP-1 is
quickly degraded by dipeptidyl peptidase-4 (DPP4) in the intes-
tinal mucosa and portal system. Metformin could potentially
increase the GLP-1 concentration by increasing its secretion
from L cells, and/or by reducing its breakdown by DPP4.
Several mouse and human in vivo studies have reported a
metformin-associated reduction in DPP4 activity [50–57].
However, in vitro studies have yet to find a direct effect of
metformin on the activity of DPP4 [58], suggesting that any
effect of metformin on DPP4 activity may be indirect, possibly
by influencing hepatic production of DPP4 [56, 64]. The results
of a number of studies have suggested that any impact of met-
formin on DPP4 activity is likely to be small. First, metformin
increases active GLP-1 levels in DPP4-deficient rats [59].
Second, DPP4 degrades both GLP-1 and gastric inhibitory
polypeptide (GIP), yet metformin treatment in humans only
increases the GLP-1 concentration, whereas DPP4 inhibitors
increase both GLP-1 and GIP concentrations [60, 61]. Third,
there is an additive effect on the GLP-1 concentration when
metformin is added to the DPP4 inhibitor sitagliptin, suggest-
ing a different mechanism of action of the two drugs [61].
Given that metformin is likely to have only a small impact
onDPP4 activity, it is likely that the main impact of metformin
on GLP-1 is to increase GLP-1 secretion. A study in mice
reported that metformin increases the expression of precursor
proteins such as preproglucagon and proglucagon in the large
intestine, potentially increasing GLP-1 production and secre-
tion [61]. Whilst one study on L cell-like lines did not support
a direct effect of metformin on L cells to mediate this effect
[60], a more recent study has reported a direct effect of met-
formin on these cells, where an increase in the expression of
the gene encoding proglucagon by metformin is mediated via
a β-catenin–TCF7L2-mediated mechanism [63, 65].
Metformin could also act indirectly to stimulate GLP-1
secretion, via alterations in the bile acid pool. Metformin in-
hibits the farnesoid X receptor (FXR) via an AMPK-mediated
mechanism, resulting in reduced sensing and ileal absorption
of bile acids [66]. The increase in the bile acid pool may then
stimulate TGR5 bile acid receptors on the L cell [62, 67],
causing an increase in GLP-1 secretion via mitochondrial ox-
idative phosphorylation and calcium influx [67].
Metformin, serotonin and histamine Metformin has some
structural similarities with selective agonists of the 5-HT3 re-
ceptor and, as outlined earlier, is in part transported by SERT.
Serotonin (5-HT) release from the intestine is associated with
nausea, vomiting and diarrhoea—symptoms similar to those
associated with metformin intolerance. Therefore, one possi-
ble mechanism for the GI intolerance associated with metfor-
min may relate to altered transport of serotonin or to a direct
serotonergic-like effect of metformin. Metformin stimulates
the release of 5-HT from enterochromaffin cells collected by
duodenal biopsy frommetformin-naive individuals [68]; how-
ever, this effect is not mediated via the 5-HT3 receptor, as
inhibition of the receptor does not alter the response. As an
alternative explanation, it could be that metformin uptake via
SERT or OCT1 results in reduced serotonin transport and
resultant GI side-effects [69]. Finally, a recent paper has iden-
tified a potential role for metformin in inhibiting diamine ox-
idase, which is highly expressed in enterocytes and responsi-
ble for metabolism of histamine [69]. Histamine, like seroto-
nin, is also associated with increased gut motility. More
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studies are required to establish the likely mechanism for GI
intolerance to metformin and, importantly, how this key side
effect can be avoided or treated.
Metformin and the gut–brain axis
A recent study in rats suggested that metformin influences the
gut–brain axis [70]. The effect of intraduodenal metformin
infusion on duodenal mucosal AMPK production and subse-
quent hepatic glucose production was assessed. The rats re-
quired an increased rate of glucose infusion to maintain
euglycaemia during clamp conditions within the first 60 min
of intraduodenal metformin administration and had a lower
hepatic glucose production. However, when metformin was
infused into the hepatic portal vein, no increase in the glucose
infusion rate was required, and there was no decrease in he-
patic glucose production over the same timeframe [70]. This
indicates that duodenal metformin has a direct, pre-absorptive
effect on glucose homeostasis in the rat. Based on this finding,
it was hypothesised that metformin activates GLP-1 receptors
to increase protein kinase A (PKA) activity on intestinal vagal
afferents. It was envisaged that the afferents transmit to
N-methyl-D-aspartate (NMDA) receptors in the nucleus of
the solitary tract (NTS), with onward signalling to the efferent
fibres of the hepatic vagal nerve, resulting in a reduction in
hepatic glucose production. The pre-absorptive effect of met-
formin was lost when each part of this neuronal pathway was
blocked using GLP-1 receptor antagonists or PKA inhibitors,
tetracaine, the NMDA receptor blocker MK-801 and hepatic
vagotomy. Although these studies were carried out in rat
models, they once again highlight the small intestine as a site
of action of metformin, and suggest a novel pathway through
which metformin may be acting. This mechanism requires
further investigation in humans.
Metformin and bile acids
Metformin increases the bile acid pool within the intestine [65,
71–75], predominantly through reduced ileal absorption [65,
72]. This disruption of the enterohepatic circulation of bile salts
has potential consequences for cholesterol homeostasis, entero-
endocrine function and glucose homeostasis. It may also con-
tribute to metformin intolerance through alterations in the
microbiome and stool consistency. In addition, as discussed
previously, the alteration in bile acid absorption may result in
increased GLP-1 secretion, in a similar way to that observed
with bile acid sequestrants such as colesevelam [76, 77].
Several studies have demonstrated reduced absorption of
bile acids in patients receiving metformin treatment and
shown this to be a direct effect of metformin on enterocytes
[65, 72–75]. Bile acid absorption in the jejunum is a passive,
non-saturable and concentration-dependent process, whereas
ileal absorption is mainly an active process [73]. FXR is a bile
acid sensor involved in ileal absorption of bile acids, as well as
the synthesis and secretion of bile acids from the liver. AMPK
binds directly to FXR and represses the receptor via direct
phosphorylation, resulting in reduced FXR transcriptional ac-
tivity and, subsequently, reduced bile acid absorption [65]. As
an AMPK activator, metformin could potentially exert effects
on the bile acid pool via FXR.
A reduction in bile acid absorption has been suggested as a
mechanism through which chronic metformin treatment can
lower cholesterol [72, 73]. It has also been suggested that an
increased luminal bile salt concentration would have an os-
motic effect, which could lead to the diarrhoea associated with
metformin treatment [72].
Metformin and the gut microbiome
The gut microbiome and the metagenome (the microbial ge-
nome) are areas receiving increasing research attention, and
are now considered as environmental factors that contribute to
the development of many diseases, including obesity, the met-
abolic syndrome and type 2 diabetes [78–84]. Large
metagenome-wide studies in China and Europe have de-
scribed gut microbial dysbiosis in association with obesity
and type 2 diabetes. Although these two studies differ in terms
of the changes they identified, a common finding was a reduc-
tion in butyrate-producing bacteria and an increase in oppor-
tunistic pathogens [78, 81]. More recently, data from these
studies and the Danish MetaHIT project were analysed after
controlling for metformin treatment [84]. This identified the
reduction in butyrate-producing taxa as a signature of gut
microbiome shifts in type 2 diabetes.
Metformin alters the microbiome in bothmice and humans,
causing an overall decrease in the bacterial diversity of the
mouse microbiome, which contrasts with the effect of a
high-fat diet [85, 86]. Studies in humans are more limited,
but in a cross-sectional study of the microbiome in women
with type 2 diabetes, those treated with metformin had a dif-
ferent microbiome compared with those not treated with the
drug (see Fig. 2) [79]. In particular, metformin treatment was
accompanied by a marked increase in the bacterium
Akkermansia muciniphila and an associated increase in
mucin-producing goblet cells. In mice, treatment with
oligofructose (resulting in an increase in A. muciniphila) or
direct treatment with A. muciniphila has been reported to im-
prove metabolic disorders, possibly by increasing
endocannabinoids, which reduce inflammation, modify gut
peptide secretion and improve the thickness of the gut mucous
barrier [82]. Administration of A. muciniphila to mice receiv-
ing a high-fat diet improved glucose tolerance [86], suggest-
ing that the effect of metformin on abundance of this species
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within in the microbiome may indirectly contribute to the
glucose-lowering effect of metformin. It has been postulated
that an increase in bacteria producing the short-chain fatty
acids butyrate and propionate may improve glycaemia [84].
Butyrate and propionate increase intestinal gluconeogenesis.
In rodents, increased intestinal gluconeogenesis results in a
reduction in hepatic gluconeogenesis, appetite and weight,
leading to improved glucose homeostasis.
An alteration in the microbiome by metformin may also be
a potential cause of GI intolerance. Burton et al carried out a
small open-label crossover study using a GImicrobiomemod-
ulator (GIMM) or placebo in conjunction with metformin in
metformin-intolerant patients with type 2 diabetes [87]. They
found that treatment with metformin in combination with
GIMM resulted in lower fasting glucose levels, suggesting
better tolerance of metformin therapy for longer or at a higher
dosage. Therefore, metformin appears to affect the
microbiome, and could potentially exert some of its chronic
pharmacodynamic effects in this manner, and an individual’s
metformin tolerance may be influenced by their microbiome.
Conclusion
Metformin is a commonly prescribed agent for the treatment
of type 2 diabetes. Although it has been in clinical use for
decades, its mechanism of action is still under investigation.
It has a complex relationship with the gut, both in terms
of drug response and drug intolerance. The efficacy of
metformin is in part mediated by the gut—potentially
by direct effects on glucose uptake and metabolism,
by directly or indirectly increasing GLP-1, by an in-
crease in bile acid exposure and by altering the micro-
biome. These findings, and recent evidence that a
delayed-release formulation of metformin with minimal
systemic absorption retains its glucose-lowering efficacy
[15], suggest that the glucose-lowering effects of met-
formin are strongly influenced by effects on the gut.
The gut is also the site of an important adverse reaction
to metformin that often limits metformin dosing or use
completely. The mechanisms for this intolerance may
relate to altered transport of serotonin or histamine, lo-
cal metformin concentrations in enterocytes, increased
bile acid exposure in the colon or an altered microbiome.
Importantly, some of the interindividual variation in
metformin tolerance can be explained by common
loss-of-function variation in the OCT1 transporter and,
potentially, co-prescribed medication. Metformin has
been in use for over 60 years. Although a number of
studies identifying a key role for metformin in the gut
were undertaken many years ago, more recent studies
have focused on metformin action in the liver, where
it undoubtedly exerts a glucose-lowering effect. Given
recent advances in our understanding of metformin
transport in the gut, the incretin system, the potential
gut–brain axis and the complexities of the microbiome,
more research in these areas would doubtless further
improve our knowledge and understanding of metformin
action and tolerance.
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